Eupraxia Pharmaceuticals (NASDAQ:EPRX) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a sell rating to a strong sell rating in a report issued on Saturday.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, William Blair started coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $6.92 on Friday. The company has a 50 day moving average of $7.29 and a 200-day moving average of $7.29. Eupraxia Pharmaceuticals has a 1-year low of $3.67 and a 1-year high of $9.32. The company has a current ratio of 19.31, a quick ratio of 15.12 and a debt-to-equity ratio of 0.02. The company has a market cap of $418.18 million, a PE ratio of -6.59 and a beta of 1.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, equities research analysts forecast that Eupraxia Pharmaceuticals will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $71,000. Bank of America Corp DE increased its position in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the period. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $76,000. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $76,000. Finally, Geode Capital Management LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $105,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.